NCT06940791View on ClinicalTrials.gov

Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2030

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Tirabrutinib

Tirabrutinib (480 mg) taken orally daily at fasting condition

DRUG

Placebo

Placebo taken orally daily at fasting condition

Trial Locations (1)

181-8611

RECRUITING

Kyorin University Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

National Cancer Center, Japan

OTHER_GOV

collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

collaborator

Japan Clinical Oncology Group

OTHER

lead

Kyorin University

OTHER